Repligen corp stock.
CI. Transcript : Repligen Corporation Presents at The Stifel 2023 Annual Healthcare Conference, Nov-15-2023 08:00 AM. Nov. 15. CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07.
Allworth Financial LP raised its holdings in Repligen by 62.7% in Q4 and now owns 262 shares of the biotechnology company’s stock valued at $44,000 after adding another 101 shares to its portfolio. Moreover, Achmea Investment Management B.V. entered into a new position with Repligen in the fourth quarter worth $49,000.CureVac N.V. -0.54%. $1.23B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Repligen Corp’s ( RGEN) price is currently down 4.66% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $160.14. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 37.23%.Investors. These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments. [email protected] Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.
Sep 29, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.
Waltham, Massachusetts 02453. Phone 1 781 250-0111. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue $801.54M. Net Income $185.96M. 2022 Sales Growth 19.54%.
See Insiders’ Hot Stocks on TipRanks >> Based on Repligen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $182.66 million and a net ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.12 thg 9, 2023 ... ... Repligen.” About Repligen Corporation Repligen Corporation is a ... Stock RGEN logo. Repligen Corp. NASDAQ:RGEN. RGEN Latest News. Oct 17, 2023.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 14.71% in the past year. Currently, Repligen Corp’s price-earnings ratio is 47.0. Repligen Corp’s trailing 12-month revenue is $777.8 million with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was -11.5%.
The stock price rose by $0.27, resulting in a percentage change of +0.61%. While this may seem like a small change, it indicates positive momentum for the company’s stock. Looking ahead, Repligen Corporation is scheduled to release its next financial report on February 15, 2024.
Repligen Corp. (NASDAQ:RGEN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in ...
While Repligen Corporation (NASDAQ:RGEN) might not be the most widely known stock at the moment, it received a lot of attention from a substantial price increase on the NASDAQGS over the last few ...Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing. Waltham, Massachusetts 02453. Phone 1 781 250-0111. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue $801.54M. Net Income $185.96M. 2022 Sales Growth 19.54%.Shares of bioprocessing technology company Repligen (RGEN 0.98%) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. ... Why Repligen Corporation Stock Is Storming Higher Today.Total revenue as reported for the full year 2022 increased to $801.5 million compared to $670.5 million for the full year 2021, a year-over-year gain of 20%, or 25% at constant currency, overall ...
Oct 3, 2023 · Repligen Corp stock has a Value Score of 5, Momentum Score of 54 and Estimate Revisions Score of 37. Comparing Agiliti Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. Find the latest Repligen Corp (RGN.MU) stock quote, history, news and other vital information to help you with your stock trading and investing.Repligen Corp’s ( RGEN) price is currently down 4.66% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $160.14. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 37.23%.Apr 25, 2023 · Shares of bioprocessing technology company Repligen (RGEN 0.98%) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. ... Why Repligen Corporation Stock Is Storming Higher Today. RGEN | AI Stock Analysis for Repligen Corp. RGEN Including Stock Price, Stock Chart, Technical, Fundamental, Sentiment Analysis and More.Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 38 and Quality Score of 71. Comparing Abbott Laboratories and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …The Growth Grade Winner: Repligen Corp. As you can clearly see from the Growth Grade breakdown above, Repligen Corp has a more attractive growth grade than Bio Rad Laboratories Inc. For investors who focus solely on how a company is growing relative to other companies in the same industry, Repligen Corp could be a good stock to add to their ...
Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins.RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Shares of the bioprocessing giant Repligen Corporation ( RGEN 4.89%) are glowing green today. Specifically, the biotech's stock was up by as much as 14.9% earlier today. Repligen's shares have ...Track Repligen Corp. (RGEN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsRepligen Corp stock has a Value Score of 5, Momentum Score of 54 and Estimate Revisions Score of 37. Comparing Agiliti Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Oct 12, 2021. The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop ...As of February 13, 2023, Repligen Corp had a $10.2 billion market capitalization, compared to the Medical Equipment, Supplies & Distribution median of $331.8 million. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 2.91% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.0.Repligen Corp stock has a Value Score of 4, Momentum Score of 73 and Quality Score of 72. Comparing Becton Dickinson and Co and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …
The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen …
Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.
Repligen Corp (RGEN) Stock Shows Positive Performance and Promising Price Forecasts in the Biopharmaceutical Industry. On November 2, 2023, Repligen Corp (RGEN) experienced positive stock performance, with analysts forecasting a potential increase in its stock price. According to data from CNN Money, there are 13 analysts …Repligen Corporation (NasdaqGS:RGEN) completed the acquisition of Bio-Flex Solutions, L.L.C. / Newton T & M Corp for $31.8 million on December 16, 2021. The purchase price of $31.8 million includes $3 million deposited into an escrow against which the Company may make claims for indemnification.Apr 25, 2023 · Shares of bioprocessing technology company Repligen (RGEN 0.98%) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. ... Why Repligen Corporation Stock Is Storming Higher Today. Oct 13, 2023 · The Growth Grade Winner: Repligen Corp. As you can clearly see from the Growth Grade breakdown above, Repligen Corp has a more attractive growth grade than Medtronic PLC. For investors who focus solely on how a company is growing relative to other companies in the same industry, Repligen Corp could be a good stock to add to their portfolio. With Repligen stock trading at $164.94 per share, the total value of Repligen stock (market capitalization) is $9.21B. Repligen stock was originally listed at a price of $0.78 in Dec 31, 1997 . If you had invested in Repligen stock at $0.78 , your return over the last 25 years would have been 21,019.08% , for an annualized return of 23.88% (not ...Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins.Inspire Medical Systems Inc. 151.72. +6.41. +4.41%. Get Repligen Corp (RGEN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Dec 1, 2023 · See the latest Repligen Corp stock price (RGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.
Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide. Currently, there are 55.54 million shares of Repligen Corp stock available for purchase. Repligen Corp’s price-earnings (P/E) ratio is currently at 49.4, which is high compared to the Medical Equipment, Supplies & Distribution industry median of 33.1. The price-earnings ratio gauges market expectation of future performance by relating a stock ...Instagram:https://instagram. d i d i stock priceally newsnyse kvyosequoia financial Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. stocks insider buyingjim cramer nvidia stock Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Currently, there are 55.54 million shares of Repligen Corp stock available for purchase. Repligen Corp’s price-earnings (P/E) ratio is currently at 49.4, which is high compared to the Medical Equipment, Supplies & Distribution industry median of 33.1. The price-earnings ratio gauges market expectation of future performance by relating a stock ... forex day trading platforms Stocks of Repligen Corp. saw a sharp rise in short interest on Nov 14, 2023 jumping by 10000.0 shares to 5.99 million. Data from Yahoo Finance shows that the short interest on Oct 12, 2023 was 5.98 million shares. A jump of 0.17% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just ...The latest Repligen stock prices, stock quotes, news, and RGEN history to help you invest and trade smarter. A vertical stack of three evenly spaced horizontal lines. ... Repligen Corp. is a ...Inspire Medical Systems Inc. 151.72. +6.41. +4.41%. Get Repligen Corp (RGEN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.